They found that a TP53 inhibitor not only inhibited the growth of tumor cells by inducing apoptosis and cell cycle arrest, but also increased the sensitivity of tumor cells to everolimus (an mTOR inhibitor). The gene discussed is MTOR; the disease is neoplasm.